Contrasting XTL Biopharmaceuticals (XTLB) and Its Peers

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare XTL Biopharmaceuticals to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Risk and Volatility

XTL Biopharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ peers have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares XTL Biopharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	-$6.97 million	-2.42
XTL Biopharmaceuticals Competitors	$716.53 million	$12.10 million	-15.00

XTL Biopharmaceuticals’ peers have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares XTL Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-12,357.18%	-197.96%	-30.56%

Institutional and Insider Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for XTL Biopharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	9834	15121	45433	1587	2.54

As a group, “Biotechnology” companies have a potential upside of 102.62%. Given XTL Biopharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its peers.

Summary

XTL Biopharmaceuticals peers beat XTL Biopharmaceuticals on 7 of the 13 factors compared.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.